Scarab Genomics LLC | Feb 7, 2019 | 1 min read
Scarab Genomics LLC, a global biotechnology company focused on developing breakthrough technologies in biomanufacturing by applying its proprietary Clean Genome® E. coli expression and production systems for the manufacturing of proteins, single chain antibodies, plasmid DNA including retroviral, lentiviral, and shRNA vectors, and RNA and Theraly Fibrosis Inc., a biopharmaceutical company with a mission to develop innovative medicines for curing fibrotic diseases, today announced that they have entered into a license agreement to allow Theraly Fibrosis to fully exploit Scarab Genomics’ technology for the production of a protein for its core therapeutic program.